Program
CHF5993
A development code. Also written as “CHF5993 100/6/12.5 μg pMDI HFA-152a”, “CHF5993 200/6/12.5 μg pMDI HFA-152a” and “CHF 5993 100/6/12.5 µg”.
Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive, led by Chiesi Farmaceutici.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chiesi Farmaceutici | 112 open or running | phase 4since Oct 12, 2021 | May 20, 2014 | Jun 3, 2027phase 2 · NCT07301736 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 20, 2014First study: phase 1 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT02287272 · 25 enrolled · Belgium
- Feb 3, 20162 phase 3 studies in AsthmaNCT02676089, NCT02676076
- Mar 31, 2016Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT02743013 · 50 enrolled · Belgium
- Jan 25, 2017Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT03197818 · 708 enrolled · China, South Korea, Taiwan
- Jun 6, 2018Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT03590379 · 366 enrolled · Bulgaria
- Oct 12, 2021Phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT05097014 · 106 enrolled · Germany
- Mar 28, 2023Phase 1 study in AsthmaNCT05830071 · 95 enrolled · United States
- Nov 13, 2023Phase 3 study in AsthmaNCT06264674 · 827 enrolled · Bulgaria, Czechia, Georgia and more
- Dec 11, 2025Phase 2 study in AsthmaNCT07301736 · 780 planned · Argentina, Bosnia and Herzegovina, Bulgaria and more
- Sep 18, 2026Phase 3 study in AsthmaNCT07858123 · 700 planned · Germany, Italy, Spain
Ahead
- Jun 3, 2027Primary completion: phase 2 study in AsthmaNCT07301736
- Jun 26, 2030Primary completion: phase 3 study in AsthmaNCT07858123
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07858123Asthma · Germany, Italy, Spain | 3 | Not yet recruiting | Jun 26, 2030 | 700 |
| NCT07301736Asthma · Argentina, Bosnia and Herzegovina, Bulgaria and more | 2 | Recruiting | Jun 3, 2027 | 780 |
| NCT06264674Asthma · Bulgaria, Czechia, Georgia and more | 3 | Completed | Feb 18, 2025 | 827 |
| NCT05830071Asthma · United States | 1 | Completed | Oct 13, 2023 | 95 |
| NCT05097014Pulmonary Disease, Chronic Obstructive · Germany | 4 | Completed | Feb 24, 2023 | 106 |
| NCT03590379Pulmonary Disease, Chronic Obstructive · Bulgaria | 2 | Completed | Oct 16, 2018 | 366 |
| NCT03197818Pulmonary Disease, Chronic Obstructive · China, South Korea, Taiwan | 3 | Completed | May 26, 2020 | 708 |
| NCT02743013Pulmonary Disease, Chronic Obstructive · Belgium | 1 | Completed | Jul 2016 | 50 |
| NCT02676089Asthma · Argentina, Belarus, Bulgaria and more | 3 | Completed | May 28, 2018 | 1,437 |
| NCT02676076Asthma · Germany | 3 | Completed | May 17, 2018 | 1,155 |
| NCT02287272Pulmonary Disease, Chronic Obstructive · Belgium | 1 | Completed | Jul 2014 | 25 |
How it is read
Names in the registry
- “CHF5993”, 2 entries
- “CHF5993 100/6/12.5 μg pMDI HFA-152a”, 1 entry
- “CHF5993 200/6/12.5 μg pMDI HFA-152a”, 1 entry
- “CHF 5993 100/6/12.5 µg”, 1 entry
- “CHF 5993 100/6/12.5”, 1 entry
Codes read as this program: CHF5993.
Conditions, from the studies’ own filings
- Asthma, 6 studies
- Pulmonary Disease, Chronic Obstructive, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.